Press Releases

Alan Krasner, M.D., chief medical officer at Crinetics, added, “We are very encouraged by these single ascending dose data that clearly demonstrate proof-of-SST5 agonism and resultant inhibition of insulin secretion with CRN04777 exposure in healthy volunteers. We are excited by the possibility that CRN04777 may serve as an oral treatment to normalize glucose levels in any child born with congenital HI regardless of their specific genetic mutation and eagerly look forward to better understanding its full potential with additional clinical studies.”

Crinetics' management will be participating in investor conferences hosted by H.C. Wainwright, SVB Leerink and Cantor Fitzgerald during the month of September.

“Jeff’s intellectual curiosity and proven ability to grow into new roles makes him a natural fit for the Crinetics team. We look forward to applying his specific expertise in operational and clinical management as we continue to advance our pipeline and increase the staff and infrastructure necessary to support the growing clinical and commercial operations.” - Scott Struthers, Ph.D. Founder, CEO - Crinetics

“We’ve seen advancements across our pipeline over the past months, with the commencement of dosing in the Phase 3 PATHFNDR-1 trial of paltusotine in acromegaly and the announcement of data from CRN04894’s Phase 1 program,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.

Crinetics ($CRNX) today announced positive interim findings from the single ascending dose (SAD) arm of a first-in-human study with CRN04894 demonstrating pharmacologic proof-of-concept for this first-in-class oral, nonpeptide adrenocorticotropic hormone (ACTH) antagonist that is being developed for the treatment of conditions of ACTH excess, including Cushing’s disease and congenital adrenal hyperplasia.